Indiana University
Bryan Schneider
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Metastatic Cancer
Advanced Cancer
Social Determinants of Health and toxicity questionnaires
This study proposes an innovative approach leveraging the molecular tumor boards across four comprehensive cancer centers, where real- world, diverse patients with metastatic cancer are seen receiving a broad scope of therapies in the context of precision medicine. The study plans to collect detailed clinical, social, and genomic data from patients to identify significant contributors of disparate survival and toxicity outcomes for patients with metastatic cancer.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 10600 participants |
| Official Title : | Evaluating Disparities in Precision Oncology: An Observational Trial in the Context of a Real-World Academic Practice Model |
| Actual Study Start Date : | 2024-01-26 |
| Estimated Primary Completion Date : | 2028-12 |
| Estimated Study Completion Date : | 2028-12 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States, 46202